NCT05275478 2026-04-15Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Terminated110 enrolled
NCT05732831 2026-04-06Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Recruiting225 enrolled
NCT07244835 2025-12-08A Study of DEG6498 in Participants With Solid TumorsDegron Therapeutics Co.Phase 1 Recruiting100 enrolled
NCT05245500 2025-12-05Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionBristol-Myers SquibbPhase 1 Recruiting336 enrolled
NCT06603987 2025-11-19Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMAStella Pharma CorporationPhase 1/2 Enrolling by invitation30 enrolled
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled